LIDE Biotech (LIDE Shanghai Biotech, Ltd.) was founded in 2011 by overseas returnees with a founding scientific philosophy centred on translational relevance: designing preclinical models that mirror clinical biology as closely as possible to improve the predictive value of preclinical data for clinical outcomes. The company is headquartered in Shanghai, China, and operates AAALAC-accredited animal facilities. Its US point of contact is accessible via a Pittsburgh, Pennsylvania telephone number, reflecting active engagement with North American and European pharmaceutical and biotechnology sponsors. The company is verified on Scientist.com, enabling direct study commissioning through that platform.

LIDE’s core scientific asset is one of the world’s largest PDX model libraries, comprising over 2,300 patient-derived xenograft models developed directly from its own patient network across more than 50 cancer types. This library includes over 400 pre-treated models, 370-plus drug-resistant models verified post-establishment, 350-plus treatment-naive models, and approximately 300 models warmed and ready for immediate in vivo use. Each model is supported by patient consent documentation, treatment history, gene mutation and expression data, growth curve data, and standard-of-care response information, accessible through an in-house precision medicine database (pMed). A dedicated model search tool allows sponsors to identify and select models by indication, genotype, or phenotype.

The company serves pharmaceutical companies, biotechnology organisations, and academic institutions across North America, Europe, and Asia, offering both full contract research programmes and individual model purchase or licensing.

Key Products and Services

Proprietary Technology Platforms

• MiniPDX® (7-Day In Vivo Organoid) — LIDE’s flagship proprietary platform, combining the biological fidelity of PDX tumour tissue with the speed and scalability advantages of an organoid format; live patient tumour tissue is encapsulated in hollow fibre capsules and implanted subcutaneously in immunodeficient mice for seven-day in vivo drug response assessment; used for hit discovery, candidate selection, and companion diagnostic applications; the IO-FIVE® variant adapts the MiniPDX platform for immuno-oncology studies, enabling evaluation of immunotherapy candidates in an in vivo context with preserved tumour immune microenvironment interactions
• OncoVee™ K-Cell 1000 Cell Kit — a companion product enabling multi-omics and transcriptomic analysis from MiniPDX and other small-sample sources, requiring as few as 1,000 cells for gene expression profiling

In Vivo Model Systems

• Patient-Derived Xenograft (PDX) Models — 2,300+ models across solid tumours and haematological malignancies; proprietary pMed database with molecular and clinical annotation; drug efficacy, PK/PD, biomarker, and combination study services
• Cell Line-Derived Xenograft (CDX) Models — 120 CDX models across major oncology indications for standardised efficacy and combination studies
• Orthotopic Models — tumour implantation at the organ of origin for anatomically relevant tumour growth and metastasis assessment
• Syngeneic Mouse Models — immunocompetent mouse tumour models for immuno-oncology evaluation in the presence of an intact murine immune system
• Humanised Models — human immune system-reconstituted mouse models enabling evaluation of human-specific immunotherapy candidates in vivo

Ex Vivo and In Vitro Models

• 3D Spheroid and Organoid Assays — patient-derived and cell line-derived three-dimensional culture models for drug screening and mechanistic studies
• Conditionally Reprogrammed (CR) Cells — patient-derived cell cultures maintaining primary tumour characteristics for in vitro drug response studies
• Co-Culture Assays for Immuno-Oncology — cellular co-culture systems enabling immune cell and tumour cell interaction studies for IO programme support

Multi-Omics and Analytical Services

• Transcription Analysis and Bioinformatics — gene expression profiling, RNA-seq, and bioinformatic analysis pipelines for biomarker identification, tumour characterisation, and drug mechanism studies
• Sequencing and Functional Genomic Imaging (FGI) — next-generation sequencing and functional genomic imaging services supporting tumour biology and target validation
• Multiplex Tissue Imaging — imaging mass cytometry and CyTOF-based multiplex tissue imaging for spatial characterisation of tumour and immune cell populations within tissue sections

Therapeutic Area and Modality Services

• Preclinical Oncology — full-spectrum solid tumour and haematological malignancy drug efficacy studies across standard-of-care and novel therapeutic candidates
• Immuno-Oncology (IO) Platform — comprehensive IO study services spanning checkpoint inhibitors, CAR-T, bispecific antibodies, and tumour vaccine candidates using syngeneic, humanised, MiniPDX, and co-culture systems
• Drug-Resistant Cancer Models — a library of over 370 drug-resistance-verified PDX models enabling resistance mechanism studies and next-line therapy evaluation; positioned as the world’s largest drug-resistant model collection
• ADC Development — preclinical efficacy and translational studies for antibody-drug conjugates, including target expression screening, ADC efficacy in PDX and CDX models, and bystander effect evaluation
• Haematological Malignancies — PDOX (patient-derived orthotopic xenograft) models of blood cancers including leukaemia, lymphoma, and myeloma

Academic and Collaborative Services

• Academic collaboration programmes with tailored pricing and publication support for university and non-profit research institutions
• Model purchase and licensing for sponsors wishing to conduct in-house studies using LIDE-developed PDX models

LIDE Biotech occupies a well-differentiated position in the oncology preclinical CRO market, built on three intersecting strengths: the scale and annotation depth of its PDX library, the scientific differentiation of its MiniPDX® platform, and a drug-resistant model collection that the company claims is the largest in the world. The PDX library’s combination of molecular annotation, treatment history, drug-resistance characterisation, and clinical-grade patient consent documentation provides a level of translational context that enables sponsors to select models that closely mirror their target patient population — a capability that is directly relevant to the industry’s increasing focus on biomarker-driven patient selection and companion diagnostic development. The MiniPDX® platform addresses a longstanding tension in preclinical oncology between model fidelity and study throughput: by enabling seven-day in vivo drug response assessment from live patient tumour tissue, it provides a translational alternative to conventional two-to-three month PDX efficacy studies for candidate screening decisions. China-based AAALAC-accredited facilities and a US telephone contact reflect a client engagement model designed to serve global sponsors with the cost and operational efficiencies of a China-based CRO.